InnovaRx Innova Health Strategies
Pricing Sign in

D89.49

Other mast cell activation disorder

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 26 never code together
D89code
Excludes1
  • hyperglobulinemia NOS (R77.1)R77.1
  • monoclonal gammopathy (of undetermined significance) (D47.2)D47.2
Excludes2
  • transplant failure and rejection (T86.-)T86.-
D89.4code
Excludes1
  • aggressive systemic mastocytosis (C96.21)C96.21
  • congenital cutaneous mastocytosis (Q82.2)Q82.2
  • (non-congenital) cutaneous mastocytosis (D47.01)D47.01
  • (indolent) systemic mastocytosis (D47.02)D47.02
  • malignant mast cell neoplasm (C96.2-)C96.2-
  • malignant mastocytoma (C96.29)C96.29
  • mast cell leukemia (C94.3-)C94.3-
  • mast cell sarcoma (C96.22)C96.22
  • mastocytoma NOS (D47.09)D47.09
  • other mast cell neoplasms of uncertain behavior (D47.09)D47.09
  • systemic mastocytosis associated with a clonal hematologic non-mast cell lineage disease (SM-AHNMD) (D47.02)D47.02
D80-D89block
Excludes1
  • autoimmune disease (systemic) NOS (M35.9)M35.9
  • functional disorders of polymorphonuclear neutrophils (D71-)D71-
  • human immunodeficiency virus [HIV] disease (B20)B20
D50-D89chapter
Excludes2
  • autoimmune disease (systemic) NOS (M35.9)M35.9
  • certain conditions originating in the perinatal period (P00-P96)P00-P96
  • complications of pregnancy, childbirth and the puerperium (O00-O9A)O00-O9A
  • congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)Q00-Q99
  • endocrine, nutritional and metabolic diseases (E00-E88)E00-E88
  • human immunodeficiency virus [HIV] disease (B20)B20
  • injury, poisoning and certain other consequences of external causes (S00-T88)S00-T88
  • neoplasms (C00-D49)C00-D49
  • symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)R00-R94

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes 4
D89.49code
Inclusion terms
  • Other mast cell activation syndrome
D80-D89block
Includes
  • defects in the complement system
  • immunodeficiency disorders, except human immunodeficiency virus [HIV] disease
  • sarcoidosis
Index entries leading here 1
  • Activation
    • mast cell (disorder) (syndrome) D89.40
Alongside this code 5 same parent — D89.4
D89.40 Mast cell activation, unspecified D89.41 Monoclonal mast cell activation syndrome D89.42 Idiopathic mast cell activation syndrome D89.43 Secondary mast cell activation D89.44 Hereditary alpha tryptasemia
Medications 1
5 Mast Cell Activation Disorders drugs

MED-RT files conditions by MeSH, which carves the world differently from ICD-10. These are name matches on this code's description, offered as candidates — not as an assertion that they are this code.

Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

CMS22HCC47 ESRD21HCC47 ESRD24HCC47 RX08HCC99

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
D89.4
Block
D80-D89
Siblings
5

Present FY2024–FY2027.